<DOC>
	<DOCNO>NCT02169544</DOCNO>
	<brief_summary>The purpose study evaluate risk infection malignancy among Rheumatoid Arthritis ( RA ) patient treat Abatacept compare RA treatment .</brief_summary>
	<brief_title>Post-marketing Study Assessing Long-Term Safety Abatacept</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patient least two claim RA ( 714.xx ) 180 day prior include index date ( baseline period ) Patient age 18 year old index date Patient enrol database least 180 day index date Patient newly prescribe Abatacept another RA treatment least two claim treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>